4th Oct 2021 07:00
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Press release
4 October 2021
Cellular Goods PLC
("Cellular Goods" or "the Company")
Director dealings & TR1 notification
Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products formulated with lab-made cannabinoids, announces that Alexis Abraham, chief executive, purchased two million ordinary shares in the Company at 7.75 pence each on 1 October 2021.
The acquisition has increased his total holding to 20.5 million shares, representing 4.1% of the issued capital in the Company, as per the notification below.
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Cellular Goods plc LEI: 213800IXPX4Z2MKX2U28 | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify)iii: | ||||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Alexis Abraham, CEO | |||||
City and country of registered office (if applicable) | ||||||
4. Full name of shareholder(s) (if different from 3.)v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reachedvi: | 1 Oct. 2021 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 1 Oct. 2021 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | |||
Resulting situation on the date on which threshold was crossed or reached | 4.1% | n/a | 504,750,000 | |||
Position of previous notification (if applicable) | 3.7% | n/a | 3.7% | 504,750,000 | ||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
GB00BK964W87 | 20,500,000 | n/a | 4.1% | n/a | |||||
SUBTOTAL 8. A | 20,500,000 | 4.1% | |||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | n/a | n/a | |||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 | n/a | n/a | |||||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | X | |||
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | ||||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional informationxvi | ||||
Place of completion | London, UK |
Date of completion | 2 Oct. 2021 |
For further information please contact:
Cellular Goods | |
Alexis Abraham Chief Executive Neil Thapar Investor Relations | +44 207 031 6871
+44 787 645 5323 |
Tennyson Securities | |
Corporate Broker Peter Krens |
+44 207 186 9030 |
Novum Securities | |
Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
Tancredi Intelligent Communication | |
Media Relations Helen Humphrey Edward Daly Salamander Davoudi |
+44 744 922 6720 +44 786 143 0057 +44 795 754 9906 |
About Cellular Goods PLC
Cellular Goods is a U.K.-based provider of premium consumer products incorporating lab-made cannabinoids. It was established in August 2018 to develop and market efficacy-led and research-backed cannabinoid products. The initial focus is on three categories: premium CBG skincare, CBD ingestibles, and CBD topical athletic recovery formulas. The first products will launch December 2021 and be available direct to consumers through the Company's website.
www.cellulargoods.co
Related Shares:
CBX.L